NASDAQ: IMCRImmunocore Holdings PLC Stock
$59.46+0.41 (+0.69%)
Updated May 2, 2024
IMCR Price
$59.46
Fair Value Price
-$0.33
Market Cap
$2.96B
52 Week Low
$42.21
52 Week High
$76.98
P/E
-52.62x
P/B
8.03x
P/S
13.39x
PEG
N/A
Dividend Yield
N/A
Revenue
$249.43M
Earnings
-$55.29M
Gross Margin
99.6%
Operating Margin
-22.35%
Profit Margin
-22.2%
Debt to Equity
0.62
Operating Cash Flow
$3M
Beta
0.75
Next Earnings
May 31, 2024
Ex-Dividend
N/A
Next Dividend
N/A
IMCR Overview
Immunocore Holdings plc develops immunotherapies for the treatment of cancer, infectious, and autoimmune diseases. It offers KIMMTRAK for the treatment of patients with unresectable or metastatic uveal melanoma. Other oncology programs include IMC-C103C, in Phase I/II dose escalation trials in patients with solid tumor cancers (non-small-cell lung, gastric, head and neck, ovarian, and synovial sarcoma cancers), and IMC-F106C, in Phase I/II dose escalation trials in patients with multiple solid tumor cancers (non-small-cell lung, small-cell lung, endometrial, ovarian, cutaneous melanoma, and breast cancers). Immunocore was founded in 1999 and is headquartered in Abingdon, UK.
Zen Score
–
Industry Average (23)
You've viewed Zen Score for 10/10 free stocks. Upgrade to Premium to see how IMCR scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
IMCR ($59.46) is overvalued by 18,225.63% relative to our estimate of its Fair Value price of -$0.33 based on Discounted Cash Flow (DCF) modelling
Below Fair Value Valuation
IMCR ($59.46) is not significantly undervalued (18,225.63%) relative to our estimate of its Fair Value price of -$0.33 based on Discounted Cash Flow (DCF) modelling, when including a healthy margin of safety
Significantly Below Fair Value Valuation
IMCR is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
There are 30 more IMCR due diligence checks available for Premium users.
Be the first to know about important IMCR news, forecast changes, insider trades & much more!
IMCR News
Valuation
IMCR fair value
Fair Value of IMCR stock based on Discounted Cash Flow (DCF)
Price
$59.46
Fair Value
-$0.33
Undervalued by
18,225.63%
IMCR ($59.46) is overvalued by... subscribe to Premium to read more.
Below Fair Value Valuation
IMCR ($59.46) is not significantly... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
IMCR is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
IMCR price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-52.62x
Industry
7.63x
Market
35.48x
IMCR price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
8.03x
Industry
5.99x
IMCR is poor value based... subscribe to Premium to read more.
P/B vs Industry Valuation
IMCR's financial health
Profit margin
Revenue
$69.7M
Net Income
-$19.2M
Profit Margin
-27.6%
IMCR's cash burn is expected... subscribe to Premium to read more.
Interest Coverage Financials
IMCR's profit margin has increased... subscribe to Premium to read more.
Profit Margin Growth Financials
Assets to liabilities
Assets
$597.0M
Liabilities
$228.2M
Debt to equity
0.62
IMCR's short-term assets ($528.82M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
IMCR's short-term assets ($528.82M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
IMCR's debt relative to shareholder... subscribe to Premium to read more.
Shrinking Debt Financials
IMCR's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
$4.0M
Investing
-$11.0M
Financing
$14.0M
IMCR's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
IMCR vs Biotech Stocks
Immunocore Holdings Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.